Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2 Withdrawn University of Texas Southwestern Medical Center

NaSingle-groupOpen-labelTreatment

Summary

Establish safety and toxicity profile and preliminary response rate of CPI-0610 in MPNST patients and correlate response with pharmacodynamics markers and BET inhibition.

Timeline

Start: 2017-05-05
Primary completion: 2018-05-17
Completion: 2018-05-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pelabresib	Small molecule	200 mg	Oral

Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

Summary

Timeline

Drugs

Indications